(Q36210926)

12 August 2017

1 reference

title

New-generation platinum drugs in the treatment of cisplatin-resistant cancers (English)

1 reference

12 August 2017

1 reference

Mark J McKeage

1

1 reference

PubMed ID

16050795

12 August 2017

language of work or name

English

0 references

publication date

1 August 2005

1 reference

Expert Opinion on Investigational Drugs

12 August 2017

1 reference

12 August 2017

14

1 reference

12 August 2017

8

1 reference

12 August 2017

1033-1046

1 reference

Cisplatin: mode of cytotoxic action and molecular basis of resistance

12 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.8.1033

Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.8.1033

Effects of spectator ligands on the specific recognition of intrastrand platinum-DNA cross-links by high mobility group box and TATA-binding proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.8.1033

Oxaliplatin clinical activity: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.8.1033

Antitumoral activity of oxaliplatin/cisplatin-based combination therapy in cisplatin-refractory germ cell cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.8.1033

Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.8.1033

An update on satraplatin: the first orally available platinum anticancer drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.8.1033

Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.8.1033

Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.8.1033

Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.8.1033

Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.8.1033

Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.8.1033

A phase II trial of JM-216 in cervical cancer: an NCIC CTG study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.8.1033

Phase I study of JM-216 (an oral platinum analogue) in combination with paclitaxel in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.8.1033

A phase I trial of the oral platinum analogue JM216 with concomitant radiotherapy in advanced malignancies of the chest

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.8.1033

In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.8.1033

AMD473 (ZD0473) exhibits marked in vitro anticancer activity in human tumor specimens taken directly from patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.8.1033

A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.8.1033

A phase II study of ZD0473 given as a short infusion every 3 weeks to patients with advanced or metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group trial, IND 129.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.8.1033

A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.8.1033

A phase I, dose escalation trial of ZD0473, a novel platinum analogue, in combination with gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.8.1033

A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.8.1033

Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and -resistant human testicular, ovarian, and gastric carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.8.1033

Lobaplatin: a new antitumour platinum drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.8.1033

Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.8.1033

A clinical screening cooperative group phase II evaluation of lobaplatin (ASTA D-19466) in advanced head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.8.1033

A trial of lobaplatin (D-19466) in platinum-resistant ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.8.1033

Lobaplatin in advanced urothelial tract tumors. The Genitourinary Group of the European Organization for Research and Treatment of Cancer (EORTC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.8.1033

Control of tumour vascular permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.8.1033

Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.8.1033

A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.8.1033

A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.8.1033

Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.8.1033

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.8.1033

Identification of non-cross-resistant platinum compounds with novel cytotoxicity profiles using the NCI anticancer drug screen and clustered image map visualizations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.8.1033

Preclinical perspectives on platinum resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.8.1033

Clinical perspectives on platinum resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.8.1033

10.1517/13543784.14.8.1033

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

16050795